12-21-2010 14:45 BJT
COPENHAGEN, Dec. 20 (Xinhua) -- Danish bio-tech company Novozymes announced Monday that it will purchase American company EMD/Merck Crop BioScience from Merck KGaA for 275 million U.S. dollars.
"We have found in EMD/Merck Crop BioScience a company that has a strong strategic fit with our existing BioAg business. In brief, it has a complementary product range and geographical scope, a strong R&D pipeline, and very talented people," Steen Riisgaard, CEO of Novozymes, said in a press release.
Novozymes' main production is focused on the production of industrial enzymes. EMD/Merck Crop BioScience's products and technologies are used to enhance biological growth using nitrogen biofertilizers.
Editor:Zheng Limin |Source: Xinhua
No comments:
Post a Comment